In causal dispositionalism, the characteristics of both medicines and patients are considered when estimating probable beneficial or adverse outcomes of treatments.

This month, Uppsala Monitoring Centre initiated a research collaboration with the Centre for Applied Philosophy of Science at the Norwegian University of Life Sciences (NMBU CAPS). The project, called CauseHealth Pharmacovigilance, will investigate causation, evidence and complexity in medicines safety. It will be funded by UMC and hosted by NMBU in Norway.

The UK Academy of Medical Sciences recommends major changes in how medical research is managed and communicated and the importance of scientific evidence in decision making.

Causality is a tricky business in pharmacovigilance. With limited numbers of adverse event reports, how are we supposed to draw conclusions about causal relationships?

UMC has entered a collaboration with Centre for Applied Philosophy of Science at the Norwegian University to investigate causation, evidence, and complexity in medicines safety.

There is much more to pharmacovigilance than the collection of numbers and data. If we really want to create a culture of drug safety, we need to start listening to patients.

UMC’s portfolio of online training courses has recently been expanded with the addition of a new module, Statistical reasoning and algorithms in pharmacovigilance.

The new episode of the Drug Safety Matters podcast is here. Find why pharmacovigilance scientists should not discount the value of intuition.